Pharmaceuticals/Chemicals Human RCT evidence

Nebivolol

Bystolic

16.9 hours

Half-life

2.5–20 mg

Typical dose

Chronic (ongoing)

Cycle length

β1-selective blocker with nitric-oxide-mediated vasodilation; BP management on-cycle.

Key takeaways

β1-selective blocker with nitric-oxide vasodilation; approved for hypertension.
~17-hour half-life, once daily; CYP2D6 status swings exposure several-fold.
SENIORS trial showed outcome benefit in elderly heart failure, not just lower BP.
Bradycardia is the dose limiter, and beta-blockers shouldn't be stopped abruptly.

Overview

What it is

Nebivolol (Bystolic) is a beta-1-selective blocker approved for hypertension, with an unusual extra mechanism: nitric-oxide-mediated vasodilation. In anabolic-steroid contexts it shows up off-label for blood-pressure and heart-rate control.

Pharmacokinetics

The plotter models a roughly 17-hour half-life with a peak near 3 hours, supporting once-daily dosing. Bioavailability and clearance vary widely with CYP2D6 metabolizer status (the plotted 54% is a midpoint), so the label individualizes dose; poor metabolizers run substantially higher levels.

What the evidence says

Approval rested on randomized hypertension trials, and the SENIORS trial added outcome benefit in elderly heart-failure patients. Compared with older beta-blockers it causes less fatigue and sexual dysfunction, but bradycardia remains the expected dose-limiting effect, and abrupt cessation after sustained use is unsafe.

Reported dosing protocols

Protocols reported in research literature and clinic/community use — informational context, not a dosing recommendation.

Use case	Dose	Route	Frequency	Duration
Hypertension (label)	5 mg start, titrate at 2-week intervals	Oral	Once daily	Chronic
BP/HR control on-cycle (community)	2.5–5 mg	Oral	Once daily	Duration of elevated BP

Pharmacokinetic summary

Model tier: Advanced (t½ + Cmax + Tmax + F)
Half-life: 16.9 hours
Cmax: 11.6 ng/mL
Tmax: 0.1 days
Bioavailability: 54%
Typical dose: 2.5–20 mg

Frequently asked questions

How is nebivolol different from older beta-blockers?

Beyond beta-1 selectivity it stimulates nitric-oxide release, producing vasodilation. Trials show less fatigue, less sexual dysfunction, and a more neutral metabolic profile than drugs like atenolol or metoprolol.

Why do some people need much lower doses?

Nebivolol is cleared by CYP2D6, and poor metabolizers reach much higher blood levels on the same dose. The label individualizes dosing for exactly this reason.

Can nebivolol be stopped suddenly?

Abrupt beta-blocker withdrawal after sustained use risks rebound tachycardia and hypertension, and is dangerous in coronary disease. Tapering over 1–2 weeks is the standard approach when discontinuing.

References

PubMed nebivolol PK
Nebivolol PK / drug-interaction study (J Clin Pharm Ther 2014) — Entry's PK source.
SENIORS trial (Eur Heart J 2005) — RCT: nebivolol reduced mortality and cardiovascular hospitalization in elderly heart-failure patients.
DailyMed — Bystolic prescribing information — Label dosing and CYP2D6 guidance.

Comments

Loading comments…